AU2022291138A1 - Methods of treating nerve agent-induced seizures - Google Patents

Methods of treating nerve agent-induced seizures Download PDF

Info

Publication number
AU2022291138A1
AU2022291138A1 AU2022291138A AU2022291138A AU2022291138A1 AU 2022291138 A1 AU2022291138 A1 AU 2022291138A1 AU 2022291138 A AU2022291138 A AU 2022291138A AU 2022291138 A AU2022291138 A AU 2022291138A AU 2022291138 A1 AU2022291138 A1 AU 2022291138A1
Authority
AU
Australia
Prior art keywords
tezampanel
benzodiazepine
hours
pharmaceutically acceptable
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022291138A
Other languages
English (en)
Inventor
Christopher Francis Toombs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proniras Corp
Original Assignee
Proniras Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proniras Corp filed Critical Proniras Corp
Publication of AU2022291138A1 publication Critical patent/AU2022291138A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022291138A 2021-06-09 2022-06-09 Methods of treating nerve agent-induced seizures Pending AU2022291138A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208885P 2021-06-09 2021-06-09
US63/208,885 2021-06-09
PCT/US2022/032783 WO2022261287A1 (en) 2021-06-09 2022-06-09 Methods of treating nerve agent-induced seizures

Publications (1)

Publication Number Publication Date
AU2022291138A1 true AU2022291138A1 (en) 2023-12-07

Family

ID=84425551

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022291138A Pending AU2022291138A1 (en) 2021-06-09 2022-06-09 Methods of treating nerve agent-induced seizures

Country Status (10)

Country Link
US (1) US20240277696A1 (https=)
EP (1) EP4352047A4 (https=)
JP (1) JP2024521430A (https=)
KR (1) KR20240022544A (https=)
CN (1) CN117836284A (https=)
AU (1) AU2022291138A1 (https=)
CA (1) CA3222575A1 (https=)
IL (1) IL309097A (https=)
MX (1) MX2023014418A (https=)
WO (1) WO2022261287A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1511741B1 (en) * 2002-04-26 2012-12-26 Eli Lilly And Company Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
US11045462B2 (en) * 2016-06-14 2021-06-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods for treating neurological conditions and exposure to nerve agents
WO2018169798A1 (en) * 2017-03-11 2018-09-20 The Regents Of The University Of California Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers

Also Published As

Publication number Publication date
IL309097A (en) 2024-02-01
WO2022261287A1 (en) 2022-12-15
JP2024521430A (ja) 2024-05-31
KR20240022544A (ko) 2024-02-20
MX2023014418A (es) 2024-02-13
CN117836284A (zh) 2024-04-05
EP4352047A4 (en) 2025-04-16
EP4352047A1 (en) 2024-04-17
US20240277696A1 (en) 2024-08-22
CA3222575A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
JP7090100B2 (ja) 疼痛の処置のための１１，１３－修飾サキシトキシン：
EP2459565B1 (en) Saxitoxin derivatives, methods and compositions for studying, imaging, and treating pain
AU2021229240B2 (en) Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
AU2020409843B2 (en) Novel compounds and their use
JP2019528259A (ja) スピロ−ラクタムｎｍｄａ受容体修飾因子およびその使用
EP3390392B1 (en) Alkyl dihydroquinoline sulfonamide compounds
CN118265710A (zh) 吡啶化合物作为kv7.2增强剂
US20180230169A1 (en) Functionalized aminobenzoboroxoles
JP5466510B2 (ja) シドノンイミン−特異的ドーパミン再摂取阻害剤およびそのドーパミン関連障害の治療における使用
US20240277696A1 (en) Methods of treating nerve agent-induced seizures
US9468620B2 (en) Methods of treating ototoxicity
AU2014237569B2 (en) Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase
JP2014527962A (ja) Ｔ型カルシウムチャネル遮断薬としてのテトラヒドロナフタレン誘導体
US8168632B2 (en) Bicyclic amide derivatives for the treatment of respiratory disorders
US9107922B2 (en) Pyrimidinecarboxamide derivatives
CN118829626A (zh) 新颖双环戊烷衍生物
TW202345831A (zh) Ｋｉｔ激酶抑制劑及其使用方法
JP3513876B2 (ja) メラトニン作用性類似物としてのインドール誘導体
TWI922934B (zh) 含氮雜環類化合物及其製備方法和應用
AU2022289008A1 (en) Methods of treating or preventing conditions associated with opiate withdrawal or opiate relapse
HK40058596A (zh) 作为钾通道调节剂的化合物及其制备和应用
HK40058596B (en) Compounds as potassium channel regulators and preparation and use thereof
WO2021216781A1 (en) Afmt analogs and their use in methods of treating parkinson's disease
NZ753451A (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
HK1142596A (en) 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses